TCM
VRTX icon

TimesSquare Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

TimesSquare Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,165
Closed -$638K – 242
2021
Q2 		$638K Buy
3,165
+200
+7% +$41.8K 0.01% 213
2021
Q1 		$637K Buy
2,965
+455
+18% +$99.9K 0.01% 212
2020
Q4 		$593K Sell
2,510
-425
-14% -$97.5K ﹤0.01% 219
2020
Q3 		$799K Sell
2,935
-13,550
-82% -$3.74M 0.01% 216
2020
Q2 		$4.79M Sell
16,485
-443,855
-96% -$120M 0.05% 205
2020
Q1 		$110M Sell
460,340
-21,530
-4% -$4.94M 1.31% 6
2019
Q4 		$106M Sell
481,870
-133,350
-22% -$27M 0.94% 17
2019
Q3 		$104M Buy
615,220
+105,030
+21% +$18.6M 0.92% 19
2019
Q2 		$93.6M Sell
510,190
-10,585
-2% -$1.85M 0.72% 37
2019
Q1 		$95.8M Buy
520,775
+49,855
+11% +$9.21M 0.74% 39
2018
Q4 		$78M Sell
470,920
-84,160
-15% -$14.6M 0.67% 44
2018
Q3 		$107M Sell
555,080
-128,730
-19% -$22.9M 0.71% 40
2018
Q2 		$116M Buy
683,810
+163,480
+31% +$25.3M 0.78% 29
2018
Q1 		$84.8M Buy
520,330
+3,315
+0.6% +$541K 0.58% 56
2017
Q4 		$77.5M Buy
517,015
+51,325
+11% +$7.6M 0.51% 70
2017
Q3 		$70.8M Sell
465,690
-24,655
-5% -$3.71M 0.47% 77
2017
Q2 		$63.2M Sell
490,345
-81,755
-14% -$9.84M 0.41% 98
2017
Q1 		$62.6M Sell
572,100
-156,600
-21% -$13.8M 0.4% 103
2016
Q4 		$53.7M Sell
728,700
-6,210
-0.8% -$505K 0.36% 109
2016
Q3 		$64.1M Buy
734,910
+25,000
+4% +$2.36M 0.41% 96
2016
Q2 		$61.1M Buy
+709,910
New +$61.3M 0.4% 99
2015
Q1 		– Sell
-900
Closed -$107K – 257
2014
Q4 		$107K Hold
900
– – ﹤0.01% 245
2014
Q3 		$101K Buy
900
+600
+200% +$57.1K ﹤0.01% 245
2014
Q2 		$28K Buy
+300
New +$21K ﹤0.01% 239

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TimesSquare Capital Management's VRTX Position: Q3 2021 in Review

TimesSquare Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 3,165 shares — an estimated $638K sold.

TimesSquare Capital Management first reported a position in VRTX in Q2 2014 and held it in 24 quarters. The position peaked at $116M in Q2 2018. 935 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • TimesSquare Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • TimesSquare Capital Management sold 3,165 Vertex Pharmaceuticals shares in Q3 2021, an estimated $638K.
  • TimesSquare Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 24 quarters.
  • TimesSquare Capital Management's Vertex Pharmaceuticals position peaked at $116M in Q2 2018.
  • 935 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on TimesSquare Capital Management's 13F filing for Q3 2021, filed 8 Nov 2021.